Early lung cancer marker shows promise:
This article was originally published in Clinica
Executive Summary
A peptide in blood or sputum could provide a sensitive marker for the early diagnosis of lung cancer. Magnus von Knebel Doeberitz of the University of Heidelberg in Germany, and colleagues used a reverse transcriptase PCR test to study 175 patients suspected of having lung cancer. They found that preprogastrin-releasing peptide was present in 50% of blood samples and 22% of sputum samples from small-cell lung cancer patients. The blood test also identified 27% of non-small-cell lung cancer patients. The findings appear in the International Journal of Cancer (April).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.